The document discusses the globalization of innovation in the pharmaceutical industry. It covers trends showing the rise of innovation capabilities in other countries. Key opportunities for pharmaceutical companies include accessing skilled workforces and scientific capabilities around the world. Drivers enabling global innovation are increasing intellectual property protections, investments in research, and partnerships across countries. Challenges include threats to intellectual property from changes in patent laws and compulsory licensing of drugs. The industry must navigate regulation and litigation while bringing new medicines to patients globally.
Клуб "Историческа лаборатория", ПГ по икономика-Шумен представи историята на училището на Патронния празник - 6 декември 2013 г. Поздравления за Мария, Йоанна, Джанел и Станислава от 9 а клас!
There is an expanding interest in repurposing and repositioning of drugs as well as how in silico methods can assist these endeavors. Recent repurposing project tendering calls by the National Center for Advancing Translational Sciences (US) and the Medical Research Council (UK) have included compound information and pharmacological data. However none of the internal company development code names were assigned to chemical structures in the official documentation. This not only abrogates in silico analysis to support repurposing but consequently necessitates data gathering and curation to assign structures. We describe here the methods results and challenges associated with this, including the fact that ~40-50% of the code names remain completely blinded. In addition we describe the in silico predictions that are enabled once the structures are accessible. Consequently we suggest approaches to encourage earlier release of name to structure mappings into the public domain.
Клуб "Историческа лаборатория", ПГ по икономика-Шумен представи историята на училището на Патронния празник - 6 декември 2013 г. Поздравления за Мария, Йоанна, Джанел и Станислава от 9 а клас!
There is an expanding interest in repurposing and repositioning of drugs as well as how in silico methods can assist these endeavors. Recent repurposing project tendering calls by the National Center for Advancing Translational Sciences (US) and the Medical Research Council (UK) have included compound information and pharmacological data. However none of the internal company development code names were assigned to chemical structures in the official documentation. This not only abrogates in silico analysis to support repurposing but consequently necessitates data gathering and curation to assign structures. We describe here the methods results and challenges associated with this, including the fact that ~40-50% of the code names remain completely blinded. In addition we describe the in silico predictions that are enabled once the structures are accessible. Consequently we suggest approaches to encourage earlier release of name to structure mappings into the public domain.
mHealth Israel_Ryo Kosaka_AIST_National Institute of Advanced Industrial Scie...Levi Shapiro
Presentation by Ryo Kosaka, Senior Research Scientist, Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST). Includes an overview of priority strategies in Life Sciences and Biotech and description of the organization of the Life Sciences and Biotech department. Recent projects include a Portable System for High-Speed DNA Quantification, Application of a cell microarray chip for clinical diagnosis and single cell analysis, Safe and Secure Artificial Heart, New diagnosis for liver fibrosis utilizing glycans, AIST ventures from the department of Life Science & Biotech as well as International cooperation.
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Cirdan
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia.
introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
Lustrumlezing paul stoffels de rol van innovatie voor de gezondheidszorg van ...Michiel Stoffels
Ter gelegenheid van het 40 jarig bestaan van de Universiteit werd een reeks lustrumlezingen georganiseerd. Voor de faculteit Gezondheid en Levenswetenschappen hadden we de eer Dr. Paul Stoffels - Worldwide Chairman , Janssen Pharmaceutical Chief Scientific Officer, Johnson & Johnson - te mogen ontvangen.
Cell-Based Assays are Revolutionizing the Healthcare Without Animal Testing A potential Market on the Rise. People can earn millions once venture into this field
UCLA CTSI Director, Steven Dubinett, MD, participated in the 11th Annual American Association for Cancer Research (AACR) Frontiers in Cancer Prevention Research International Conference and discussed the advantages of the CTSI during his educational session on “The Clinical and Translational Science Award Program: Transdisciplinary Teams in Cancer Prevention Research” on Tuesday, October 16th.
Early phase drug development and the fda roadmap final version 2axE. Dennis Bashaw
This is the slide deck used in my webinar that was presented on 2/1/2018 on the FDA Predictive Toxicology Roadmap. It was presented at a webinar hosted by BioIVT in my private capacity and is not an official statement of FDA policy
John Quackenbush, PhD, a professor of biostatistics and computational biology talks about genomics, the human genome and what the study of it means for our understanding of diseases and, specifically, cancer.
1. Globalization of Innovation:
Opportunities, Enablers and
Challenges
Daniel Getman, Ph.D.
Vice-President, Pfizer Global Research and Development
Director, St Louis Laboratories
2. Globalization of Innovation:
Opportunities, Enablers and Challenges
Background on Pharmaceutical Industry
Trends and Opportunities
Drivers and Enablers
Accessing Innovation Globally
Threats to Innovation
3. New Medicines: Innovation-Driven
High Risk and Very Expensive
What’s behind the little white pill?
Typical Net Cost: $1.3 Billion*
Invested Over 10 - 15 years
* A. DiMasi and H.G. Grabowski: Managerial and Decision Economics 28 (2007), 469-479.
4. The Long Road to a New Medicine
1) Ensure Safety
2) Does it work? File New Drug
1) Ensure Safety Application
Phase 3 3) Select dose
2) Does it work? With FDA
Patients (1000s)
1) Ensure Safety 1) Seek FDA OK
2) Dosing Frequency 2) Go to Humans
Phase 2 Phase 1 Make sure
Patients (100s) Healthy Volunteers (10s)
it’s safe
Understand 1) Identify Lead
Biology and 2) Optimize Lead
Disease
3) File patents
5. Does it work in humans?
Mechanism Disease
Selective COX-2 Inhibition Pain and Inflammation
PDE5 Inhibition Erectile Dysfunction,
Pulmonary Hypertension
Alpha 2 Delta Epilepsy, Neuropathic Pain,
Anxiety, Sleep Disorders
Our Work Nicotine Partial Agonist Smoking Cessation
Validates or
Disproves Tyrosine Kinase Inhibition Cancer
Medical CCR5 Antagonism HIV - AIDS
Hypotheses
6. Sutent
Gastrointestinal Stromal Tumor and
Renal Cell Carcinoma
Strong Efficacy in Refractory GIST
7 Days
50 mg/d
Sutent
Source: Demetri, ASCO Virtual Meeting, 2003
Approved in US: Jan 2006
7. United States Life Expectancy
1900 - 47 yrs
2003 - 77.6 yrs
Factors Affecting Life Expectancy:
Improved Sanitation
Improved Nutrition
Our Work Medical Innovation
Impacts
People’s
Lives
8. Examples of Medical Innovation
Vaccines Cardiovascular
Drugs
Penicillin HIV/AIDS
and
Antibiotics
Cancer
9. Current Worldwide
Life Expectancy
Factors Affecting Life Expectancy
Sanitation
Nutrition
Medical Innovation
11. Globalization of Innovation:
Opportunities, Enablers and Challenges
Background on Pharmaceutical Industry
Trends and Opportunities
Drivers and Enablers
Accessing Innovation Globally
Threats to Innovation
12. Trends and Opportunities
“The U.S. remains the world leader in scientific
and technological innovation, but its dominance is
threatened by economic development elsewhere,
particularly in Asia.”
January 16, 2008
Citing a NSF report
http://www.nsf.gov/statistics/seind08/
National Science Board: Science and Engineering Indicators 2008
13. First university natural sciences degrees,
by selected country:
1985–2005
United States
China
SOURCE: National Science Board,
Science and Engineering Indicators 2008
14. Math and Science scores,
grades 4 and 8, and
15-yr-old students: 2003
SOURCE: National Science Board,
Science and Engineering Indicators
2008
15. Estimated R&D expenditures and
share of world total, by region: 2002
37% 29%
30%
SOURCE: National Science Board, Science and Engineering Indicators 2008
16. Globalization of Innovation
“We intend to make our
internal capability even more
effective by tapping into the
best scientific capability
outside of our walls -
wherever it exists. That’s why
we are reaching out to
scientists around the world.”
- Jeff Kindler
Pfizer Chairman & CEO
17. Globalization of Innovation:
Opportunities, Enablers and Challenges
Background on Pharmaceutical Industry
Trends and Opportunities
Drivers and Enablers
Accessing Innovation Globally
Threats to Innovation
18. Drivers and Enablers
Increasingly skilled workforce
Return of experienced scientists
Emerging capabilities
Strong government support and investment
State-of-the-art facilities and equipment
Increasing intellectual property rights
Participate in growing markets
Brazil, Russia, Korea, India, China
Internet and communications
Increased bandwidth and lower costs
Lower cost – but will likely increase over time
19. Globalization of Innovation:
Opportunities, Enablers and Challenges
Background on Pharmaceutical Industry
Trends and Opportunities
Drivers and Enablers
Accessing Innovation Globally
Threats to Innovation
20. Our Global Organization
Major Research Sites Worldwide
RTC
Rinat, SF Cambridge, MA Sandwich, UK Tokyo,
Japan
LaJolla, CA Groton, CT Shanghai,
China
CA St Louis, MO
Incubator
Singapore
> 11,000 Researchers Worldwide
> $7.5B Annual R&D Investment
21. Biotherapeutics & Bioinnovation Center
A new model for drug discovery
San Francisco
Research Unit
Collaborations TBD
Incubator
Portfolio Company Cell
Biology
RGo
Rinat
RNAi
Fabrus
San Diego
Scripps
CovX BBC RTC TBD Boston
Stem Cells
Wintherex
MIT
Coley
TBD Stem Cells
Current TBD
TBD
Planned
Asia Europe
22. The Pfizer Incubator
www.thepfizerincubator.com/index.html
Founder(s) TPI acquires
IP, know-how NewCo exclusive rights
Executes
Research
TPI Plan
Funding, facilities, Spin out
operational support
Entity Creation Incubation Exit Scenarios
23. Drug Pfinder®
An Innovative Partnership
A Partnership with academia to internalize novel targets
Pfizer gets … The collaborator gets …
University
• Jump-start Discovery projects •Access to Pfizer’s screening
expertise and chemical collection
• Access to attractive targets
• Chemical tools for basic science
• Intellectual property
• Research funding
• Expertise, reagents, tools
• Involvement in drug discovery
• Relationships
• Relationships
www.drugpfinder.com
24. Bend Research Inc. – Pfizer Licensing Opportunity
Spray-Dried Dispersion (SDD)
www.bendres.com
This initiative provides an
opportunity for companies
to advance problematic
low-solubility compounds
that otherwise stall in
development, or require
medicinal chemistry
intervention.
3 Stages
Stage 1: Non-Confidential Technical Evaluation
Stage 2: Feasibility Study
Stage 3: Pfizer License & Option Negotiation
25. Translational Medicine Call for Proposals
www.pfizer.com/translationalmedicine
1
Pfizer identifies problem to
address and completes Request
For Proposal (RFP) Template
2
RFP on public website and
distributed to known potential
partners
3
Proposals received, reviewed
Pfizer and winner selected.
manages
Agreements completed with
alliance
through a center(s).
milestone- 4
driven Center completes required
collaboration studies to solve the problem any
research plan modifications
jointly agreed
Oncology Measures of Anti-Tumor Efficacy and Apoptosis
Inflammation Biomarkers for Disease-Modifying Anti-Rheumatic Drugs
Ophthalmology Ocular Blood Flow and Glaucoma
Neurosciences Exposure/EEG Response Data (Schizophrenia and Alzheimer's)
26. Strategic Investments in China
4 Wholly-Owned factories Pfizer R&D China Pfizer Foundation-
at Dalian, Wuxi and Suzhou Established R&D hospital management
program with Peking
Dalian factory is the first center in Shanghai
university
to pass GMP in China with nearly 200
employees in 2008 Established in 2004,
have trained
hundreds of hospital
directors in 4 years
Pfizer is one of the biggest Multi-National Companies in China
with total investments exceeding US$ 500M
28. Pfizer Clinical Research Units (CRUs)
1 Unit with 3 sites
Innovation through Standardization!!!
Operate identically (systems, SOPs, medical practice, etc.)
Highly standardized & technologically most advanced:
On-line, real time data capture
Data lock 24 hrs after Last Subject Last Visit
Speed to quality decisions
29. Globalization of Innovation:
Opportunities, Enablers and Challenges
Background on Pharmaceutical Industry
Trends and Opportunities
Drivers and Enablers
Accessing Innovation Globally
Threats to Innovation
30. Some Challenges we face as an industry
Threats to Biomedical Innovation
Life Sciences is a innovation – driven industry
Create and maintain a supportive environment
Intellectual Price
Property Controls
Issues
Increasing Restricted
Litigation Government Access to
Regulation Medicines
31. The Long Road to a New Medicine
1) Ensure Safety
2) Does it work? File New Drug
1) Ensure Safety Application
Phase 3 3) Select dose
2) Does it work? With FDA
Patients (1000s)
1) Ensure Safety 1) Seek FDA OK
2) Dosing Frequency 2) Go to Humans
Phase 2 Phase 1 Make sure
Patients (100s) Healthy Volunteers (10s)
it’s safe
1) Identify Lead
Understand 2) Optimize Lead
Biology and 3) File patents
Disease
32. Intellectual Property - Globally
Some challenges we face
2008:
Potential changes to U.S. Patent Law
2007:
U.S. Supreme Court ruling on KSR International Co. v.
Teleflex Inc.
2006:
Compulsory licenses declared in medium income countries
(Thailand and Brazil)
2006:
India rejects Novartis Glivec patent
1994:
Agreement on TRIPS (Trade Related Aspects of Intellectual
Property Rights) – international agreement administered by
WTO (World Trade Organization)
Contains requirements that nations’ laws must meet for
Intellectual Property